The effect of atorvastatin on serum myeloperoxidase and CRP levels in patients with acute coronary syndrome

Clinica Chimica Acta

Volumn 368, Issue 1-2, 2006, Pages 168-172

  Zhou, Tao ^a   Zhou, Sheng hua ^a   Qi, Shu shan ^a   Shen, Xiang qian ^a   Zeng, Gao feng ^a   Zhou, Hong nian ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

3 Hydroxy 3 methylglutaryl coenzyme A reductase inhibitors; Acute coronary syndrome; C reactive protein; Inflammation; Myeloperoxidase

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ACETYLSALICYLIC ACID; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOW MOLECULAR WEIGHT HEPARIN; MYELOPEROXIDASE; NITRIC ACID DERIVATIVE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; ENZYME BLOOD LEVEL; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; TURBIDIMETRY;

ACUTE DISEASE; C-REACTIVE PROTEIN; CORONARY DISEASE; FEMALE; HEPTANOIC ACIDS; HUMANS; LIPID METABOLISM; MIDDLE AGED; PEROXIDASE; PYRROLES; SYNDROME;

EID: 33646841215     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2005.12.040     Document Type: Article

References (29)

1. Libby P., Ridker P.M., and Maseri A. Inflammation and atherosclerosis. Circulation 105 (2002) 1135-1143
2. Dinerman J.L., Mehta J.L., Saldeen T.G., et al. Increased neutrophil elastase release in unstable angina pectoris and acute myocardial infarction. J Am Coll Cardiol 15 (1990) 1559-1563
3. Buffon A., Biasucci L.M., Liuzzo G., D'Onofrio G., Crea F., and Maseri A. Widespread coronary inflammation in unstable angina. N Engl J Med 347 1 (2002 (Jul 4)) 5-12
4. Davies M.J., and Thomas A. Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. N Engl J Med 310 (1984) 1137-1140
5. Naruko T., Ueda M., Haze K., et al. Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation 106 (2002) 2894-2900
6. Zhang R., Brennan M.L., Fu X., et al. Association between myeloperoxidase levels and risk of coronary disease. JAMA 286 (2001) 2136-2142
7. Podrez E.A., Schmidt D., Hoff H.F., and Hazen S.L. Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J Clin Invest 103 (1999) 1547-1560
8. Podrez E.A., Poliakov E., Shen Z., et al. A novel family of atherogenic oxidized phospholipids promotes macrophage foam cell formation via the scavenger receptor CD36 and is enriched in atherosclerotic lesions. J Biol Chem 277 (2002) 38517-38523
9. Shabani F., Mcneil J., and Tippett L. The oxidative inactivation of tissue inhibitor of metalloproteinase-1 (TIMP-1) by hypochlorous acid (HOCL) is suppressed by anti-rheumatic drugs. Free Radic Res 28 (1998) 115-123
10. Fu X., Kassim S.Y., Parks W.C., and Heinecke J.W. Hypochlorous acid oxygenates the cysteine switch domain of pro-matrilysin (MMP-7): a mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase. J Biol Chem 276 (2001) 41279-41287
11. Baldus S., Heeschen C., Meinertz T., et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 108 (2003) 1440-1445
12. Brennan M.L., Penn M.S., Van Lente F., et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 349 (2003) 1595-1604
13. Schwartz G.G., Olsson A.G., Ezekowitz M.D., et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285 (2001) 1711-1718
14. Aikawa M., Rabkin E., Sugiyama S., et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 103 (2001) 276-283
15. Sukhova G., Williams J.K., and Libby P. Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol. Arterioscler Thromb Vasc Biol 22 (2002) 1452-1458
16. Crisby M., Nordin-Fredriksson G., Shah P.K., Yano J., Zhu J., and Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 103 (2001) 926-933
17. Albert M.A., Danielson E., Rifai N., Ridker P.M., and PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 286 (2001) 64-70
18. Gabay C., and Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340 (1999) 448-454
19. Klebanoff S.J. Myeloperoxidase. Proc Assoc Am Physicians 111 (1999) 383-389
20. Hazen S.L. Myeloperoxidase and plaque vulnerability. Arterioscler Thromb Vasc Biol 24 (2004) 1143-1146
21. Nicholls S.J., and Hazen S.L. The role of myeloperoxidase in the pathogenesis of coronary artery disease. Jpn J Infect Dis 57 (2004) S21-S22
22. Panzenboeck U., Raitmayer S., Reicher H., et al. Effects of reagent and enzymatically generated hypochlorite on physicochemical and metabolic properties of high density lipoproteins. J Biol Chem. 272 (1997) 29711-29720
23. Farb A., Burke A.P., Tang A.L., et al. Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death. Circulation 93 (1996) 1354-1363
24. Daugherty A., Dunn J.L., Rateri D.L., and Heinecke J.W. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 94 (1994) 437-444
25. Sugiyama S., Okada Y., Sukhova G.K., Virmani R., Heinecke J.W., and Libby P. Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol 158 (2001) 879-891
26. Sugiyama S., Kugiyama K., Aikawa M., Nakamura S., Ogawa H., and Libby P. Hypochlorous acid, a macrophage product, induces endothelial apoptosis and tissue factor expression. Arterioscler Thromb Vasc Biol 24 (2004) 1309-1314
27. Shishehbor M.H., Brennan M.L., Aviles R.J., et al. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation 108 (2003) 426-431
28. Rezaie-Majd A., Prager G.W., Bucek R.A., et al. Simvastatin reduces the expression of adhesion molecules in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 23 (2003) 397-403
29. van Wissen S., Trip M.D., Smilde T.J., de Graaf J., Stalenhoef A.F., and Kastelein J.J. Differential hs-CRP reduction in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapy. Atherosclerosis 165 (2002) 361-366